查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1662632

2030 年生物製藥自動化市場預測：按組件、自動化模式、技術、應用、最終用戶和地區進行的全球分析

Automation in Biopharma Market Forecasts to 2030 - Global Analysis By Component, Mode of Automation, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預測期內全球生物製藥自動化市場複合年成長率為 8.4%。

生物製藥自動化是指利用先進的技術和系統來簡化和最佳化生物製藥生產中的各個流程。這包括自動化細胞培養、蛋白質生產、品管、資料分析和包裝等任務。透過整合機器人、人工智慧和機器學習，自動化可以提高效率、減少人為錯誤、提高一致性並縮短新藥的上市時間。自動化在確保生物製藥行業的法規遵循和成本效益製造方面發揮關鍵作用。

個人化醫療需求日益成長

個人化醫療的需求不斷成長，推動市場需求。個人化治療，例如基因療法和客製化生技藥品，需要高度專業化和可擴展的製造流程，以滿足個別患者的需求。自動化有助於精確控制這些複雜過程，確保一致性和效率。透過提高生產能力並減少人為錯誤，自動化可以幫助生物製藥公司滿足日益成長的個人化治療需求，同時確保高品質標準。

資料安全和隱私問題

生物製藥自動化中的資料安全和隱私問題可能導致重大風險，包括未授權存取敏感病患資訊、智慧財產權竊盜和不遵守法規。違規行為可能導致聲譽受損、高額罰款以及失去相關人員的信任。資料保護不力也會阻礙創新和協作，因為公司可能不願意共用關鍵訊息，最終減緩藥物開發並影響市場競爭。

提高資料品質和一致性

提高市場資料的品質和一致性可以改善決策、法規遵循和業務效率。透過整合人工智慧和機器學習等先進技術，企業可以最大限度地減少人為錯誤，簡化資料收集，並確保即時資料的準確性。這將帶來更可靠的流程、更快的藥物開發和最佳化的製造——最終縮短上市時間並降低成本，同時保持高品質和安全性。

初期投資成本高

市場上高昂的初始投資成本可能是中小企業面臨的一大障礙。先進技術、設備和基礎設施的高昂前期成本可能會減緩或阻礙其採用。這可能導致創新放緩、競爭減少和財務壓力增加。小型企業可能難以獲得融資，從而阻礙其擴大規模、提高效率和跟上行業巨頭的能力。

COVID-19 的影響

COVID-19 疫情加速了市場發展，並凸顯了對更快、更有效率的藥物開發和製造流程的需求。自動化有助於簡化疫苗製造、臨床測試和供應鏈管理。然而，疫情擾亂了全球供應鏈，也導致新技術的採用出現延遲和挑戰。儘管存在這些障礙，但這場危機凸顯了自動化在增強生物製藥業務的彈性和可擴展性方面的作用。

預計預測期內自動化軟體部分將實現最大幅度成長。

預計預測期內自動化軟體部分將佔據最大的市場佔有率。整合人工智慧、機器學習和資料分析等技術，以提高效率、減少錯誤並確保法規符合。透過自動執行重複任務，這些軟體解決方案可以提高資料收集的準確性、加快生產進度並支援即時監控。這最終意味著生物製藥產業成本降低、產品上市縮短時間、產品品質提升。

預計預測期內製藥公司部門將以最高的複合年成長率成長。

預計製藥公司部門在預測期內將呈現最高的成長率。整合機器人、人工智慧和機器學習等自動化工具可以提高準確性、減少人為錯誤並加快生產流程。這些公司專注於最佳化供應鏈、臨床測試和品管。自動化不僅降低了營運成本，還加速了創新並縮短了關鍵治療方法和療法的上市時間。

比最大的地區

由於技術進步以及對更高效的藥物生產和開發流程的需求，預計北美地區將在預測期內佔據最大的市場佔有率。對人工智慧、機器人和資料分析的大力投資正在幫助北美公司最佳化製造、加強品管並確保法規合規。該地區注重創新，加上強大的醫療保健基礎設施，使其成為生物製藥自動化領域的全球領導者。

複合年成長率最高的地區

預計預測期內亞太地區將呈現最高的複合年成長率。對生技藥品、生物相似藥和先進療法的需求不斷成長，推動生物製藥公司採用自動化技術來簡化生產流程、提高一致性和規模化生產。此外，先進技術的發展增強了自動化系統，使其更易於生物製藥行業使用和適應。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球生物製藥自動化市場（按組件）

  • 介紹
  • 自動化硬體
  • 自動化軟體
  • 服務計劃階段
  • 服務營運階段
  • 分析自動化
  • 其他

6. 全球生物製藥自動化市場（依自動化模式）

  • 介紹
  • 全自動系統
  • 半自動系統

7. 全球生物製藥自動化市場（按技術）

  • 介紹
  • 自動化技術
    • 流程自動化
    • 實驗室自動化
    • 機器人和人工智慧
    • 控制系統
    • 可程式邏輯控制器（PLC）
  • 數位化技術
    • 資料分析與視覺化
    • 電子實驗室筆記本 (ELN)
    • 雲端運算
    • 物聯網 (IoT)
    • 數位雙胞胎技術

8. 全球生物製藥自動化市場（按應用）

  • 介紹
  • 研究與開發
    • 藥物研發
    • 基因組學和蛋白​​質組學
  • 生物製造
    • 上游加工
    • 下游加工
  • 實驗室測試
  • 品管和保證
  • 診斷
  • 其他

第9章。

  • 介紹
  • 製藥公司
  • 生物製藥公司
  • 合約研究組織 (CRO)
  • 學術研究所
  • 診斷實驗室
  • 其他

第 10 章。

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Danaher Corporation
  • GE HealthCare Technologies Inc.
  • PerkinElmer, Inc.
  • Tecan Group Ltd.
  • Sartorius AG
  • Agilent Technologies, Inc.
  • Hamilton Company
  • Bio-Rad Laboratories, Inc.
  • Eppendorf AG
  • Bruker Corporation
  • Honeywell International Inc.
  • Parker Hannifin Corporation
  • Rockwell Automation, Inc.
  • Waters Corporation
  • Yokogawa Electric Corporation
Product Code: SMRC28493

According to Stratistics MRC, the Global Automation in Biopharma Market is growing at a CAGR of 8.4% during the forecast period. Automation in biopharma is the use of advanced technologies and systems to streamline and optimize various processes in the production of biopharmaceuticals. This includes automating tasks such as cell culture, protein production, quality control, data analysis, and packaging. By integrating robotics, artificial intelligence, and machine learning, automation enhances efficiency, reduces human error, improves consistency, and accelerates time-to-market for new drugs. It plays a crucial role in ensuring regulatory compliance and cost-effective manufacturing in the biopharmaceutical industry.

Market Dynamics:

Driver:

Growing demand for personalized medicine

The growing demand for personalized medicine is driving the need for market. Personalized treatments require highly specific and scalable manufacturing processes to cater to individual patient needs, such as gene therapies and customized biologics. Automation facilitates the precise control of these complex processes, ensuring consistency, and efficiency. By enhancing production capabilities and reducing human error, automation enables biopharma companies to meet the increasing demand for tailored therapies, while ensuring high-quality standards.

Restraint:

Data security and privacy concerns

Data security and privacy concerns in biopharma automation can lead to significant risks, including unauthorized access to sensitive patient information, intellectual property theft, and regulatory violations. Breaches may result in reputational damage, costly fines, and loss of trust from stakeholders. Inadequate data protection can also hinder innovation and collaboration, as companies may be reluctant to share critical information, ultimately delaying drug development and affecting market competitiveness.

Opportunity:

Improved data quality and consistency

Improved data quality and consistency in the market enhances decision-making, regulatory compliance, and operational efficiency. By integrating advanced technologies such as AI and machine learning, companies can minimize human errors, streamline data collection, and ensure real-time data accuracy. This leads to more reliable processes, faster drug development, and optimized manufacturing, ultimately accelerating time-to-market and reducing costs while maintaining high standards of quality and safety.

Threat:

High initial investment costs

High initial investment costs in the market can be a significant barrier for smaller companies. The substantial upfront expenses for advanced technologies, equipment, and infrastructure may delay or prevent adoption. This can result in slower innovation, reduced competitiveness, and increased financial pressure. Smaller firms may struggle to secure funding, hindering their ability to scale operations, improve efficiency, and keep pace with larger industry players.

Covid-19 Impact:

The COVID-19 pandemic accelerated the adoption of the market, highlighting the need for faster, more efficient drug development and manufacturing processes. Automation helped streamline vaccine production, clinical trials, and supply chain management. However, the pandemic also disrupted global supply chains, leading to delays and challenges in deploying new technologies. Despite these hurdles, the crisis underscored automation's role in enhancing resilience and scalability in biopharma operations.

The automation software segment is expected to be the largest during the forecast period

The automation software segment is expected to account for the largest market share during the forecast period. It integrates technologies like AI, machine learning, and data analytics to improve efficiency, reduce errors, and ensure regulatory compliance. By automating repetitive tasks, these software solutions enhance accuracy in data collection, speed up production timelines, and support real-time monitoring. This ultimately leads to lower costs, faster time-to-market, and higher product quality in the biopharma industry.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate. By integrating automation tools like robotics, AI, and machine learning, they improve accuracy, reduce human error, and speed up production processes. These companies focus on optimizing supply chains, clinical trials, and quality control. Automation not only lowers operational costs but also accelerates innovation, ensuring faster time-to-market for critical therapies and treatments.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share driven by technological advancements and the need for more efficient drug production and development processes. With strong investments in AI, robotics, and data analytics, North American companies are optimizing manufacturing, enhancing quality control, and ensuring regulatory compliance. The region's focus on innovation, coupled with a robust healthcare infrastructure, positions it as a global leader in biopharma automation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. The growing demand for biologics, biosimilars, and advanced therapies is pushing biopharmaceutical companies to adopt automation technologies to streamline production processes, improve consistency, and meet high production volumes. Additionally, the development of advanced technologies has enhanced automation systems, making them more accessible and adaptable to the biopharmaceutical industry.

Key players in the market

Some of the key players in Automation in Biopharma market include Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, GE HealthCare Technologies Inc., PerkinElmer, Inc., Tecan Group Ltd., Sartorius AG, Agilent Technologies, Inc., Hamilton Company, Bio-Rad Laboratories, Inc., Eppendorf AG, Bruker Corporation, Honeywell International Inc., Parker Hannifin Corporation, Rockwell Automation, Inc., Waters Corporation and Yokogawa Electric Corporation.

Key Developments:

In December 2024, Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. The acquired company will be known as Advanced Accelerator Applications, a Siemens Healthineers company.

In June 2024, Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific(TM) KingFisher(TM) PlasmidPro Maxi Processor* (PlasmidPro), the only fully automated maxi-scale plasmid DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi scale purification and delivering high-purity plasmid without manual column preparation and intervention.

Components Covered:

  • Automation Hardware
  • Automation Software
  • Services Project Phase
  • Services Operation Phase
  • Analytics Automation
  • Other Components

Mode of Automations Covered:

  • Fully Automated Systems
  • Semi-Automated Systems

Technologies Covered:

  • Automation Technology
  • Digitization Technology

Applications Covered:

  • Research & Development
  • Biomanufacturing
  • Clinical Trials
  • Quality Control & Assurance
  • Diagnostics
  • Other Applications

End Users Covered:

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutions
  • Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Automation in Biopharma Market, By Component

  • 5.1 Introduction
  • 5.2 Automation Hardware
  • 5.3 Automation Software
  • 5.4 Services Project Phase
  • 5.5 Services Operation Phase
  • 5.6 Analytics Automation
  • 5.7 Other Components

6 Global Automation in Biopharma Market, By Mode of Automation

  • 6.1 Introduction
  • 6.2 Fully Automated Systems
  • 6.3 Semi-Automated Systems

7 Global Automation in Biopharma Market, By Technology

  • 7.1 Introduction
  • 7.2 Automation Technology
    • 7.2.1 Process Automation
    • 7.2.2 Laboratory Automation
    • 7.2.3 Robotics and Artificial Intelligence
    • 7.2.4 Control Systems
    • 7.2.5 Programmable Logic Controllers (PLCs)
  • 7.3 Digitization Technology
    • 7.3.1 Data Analytics and Visualization
    • 7.3.2 Electronic Lab Notebooks (ELN)
    • 7.3.3 Cloud Computing
    • 7.3.4 Internet of Things (IoT)
    • 7.3.5 Digital Twin Technology

8 Global Automation in Biopharma Market, By Application

  • 8.1 Introduction
  • 8.2 Research & Development
    • 8.2.1 Drug Discovery
    • 8.2.2 Genomics and Proteomics
  • 8.3 Biomanufacturing
    • 8.3.1 Upstream Processing
    • 8.3.2 Downstream Processing
  • 8.4 Clinical Trials
  • 8.5 Quality Control & Assurance
  • 8.6 Diagnostics
  • 8.7 Other Applications

9 Global Automation in Biopharma Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
  • 9.3 Biopharmaceutical Companies
  • 9.4 Contract Research Organizations (CROs)
  • 9.5 Academic and Research Institutions
  • 9.6 Diagnostic Laboratories
  • 9.7 Other End Users

10 Global Automation in Biopharma Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 Siemens Healthineers AG
  • 12.3 Danaher Corporation
  • 12.4 GE HealthCare Technologies Inc.
  • 12.5 PerkinElmer, Inc.
  • 12.6 Tecan Group Ltd.
  • 12.7 Sartorius AG
  • 12.8 Agilent Technologies, Inc.
  • 12.9 Hamilton Company
  • 12.10 Bio-Rad Laboratories, Inc.
  • 12.11 Eppendorf AG
  • 12.12 Bruker Corporation
  • 12.13 Honeywell International Inc.
  • 12.14 Parker Hannifin Corporation
  • 12.15 Rockwell Automation, Inc.
  • 12.16 Waters Corporation
  • 12.17 Yokogawa Electric Corporation

List of Tables

  • Table 1 Global Automation in Biopharma Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Automation in Biopharma Market Outlook, By Component (2022-2030) ($MN)
  • Table 3 Global Automation in Biopharma Market Outlook, By Automation Hardware (2022-2030) ($MN)
  • Table 4 Global Automation in Biopharma Market Outlook, By Automation Software (2022-2030) ($MN)
  • Table 5 Global Automation in Biopharma Market Outlook, By Services Project Phase (2022-2030) ($MN)
  • Table 6 Global Automation in Biopharma Market Outlook, By Services Operation Phase (2022-2030) ($MN)
  • Table 7 Global Automation in Biopharma Market Outlook, By Analytics Automation (2022-2030) ($MN)
  • Table 8 Global Automation in Biopharma Market Outlook, By Other Components (2022-2030) ($MN)
  • Table 9 Global Automation in Biopharma Market Outlook, By Mode of Automation (2022-2030) ($MN)
  • Table 10 Global Automation in Biopharma Market Outlook, By Fully Automated Systems (2022-2030) ($MN)
  • Table 11 Global Automation in Biopharma Market Outlook, By Semi-Automated Systems (2022-2030) ($MN)
  • Table 12 Global Automation in Biopharma Market Outlook, By Technology (2022-2030) ($MN)
  • Table 13 Global Automation in Biopharma Market Outlook, By Automation Technology (2022-2030) ($MN)
  • Table 14 Global Automation in Biopharma Market Outlook, By Process Automation (2022-2030) ($MN)
  • Table 15 Global Automation in Biopharma Market Outlook, By Laboratory Automation (2022-2030) ($MN)
  • Table 16 Global Automation in Biopharma Market Outlook, By Robotics and Artificial Intelligence (2022-2030) ($MN)
  • Table 17 Global Automation in Biopharma Market Outlook, By Control Systems (2022-2030) ($MN)
  • Table 18 Global Automation in Biopharma Market Outlook, By Programmable Logic Controllers (PLCs) (2022-2030) ($MN)
  • Table 19 Global Automation in Biopharma Market Outlook, By Digitization Technology (2022-2030) ($MN)
  • Table 20 Global Automation in Biopharma Market Outlook, By Data Analytics and Visualization (2022-2030) ($MN)
  • Table 21 Global Automation in Biopharma Market Outlook, By Electronic Lab Notebooks (ELN) (2022-2030) ($MN)
  • Table 22 Global Automation in Biopharma Market Outlook, By Cloud Computing (2022-2030) ($MN)
  • Table 23 Global Automation in Biopharma Market Outlook, By Internet of Things (IoT) (2022-2030) ($MN)
  • Table 24 Global Automation in Biopharma Market Outlook, By Digital Twin Technology (2022-2030) ($MN)
  • Table 25 Global Automation in Biopharma Market Outlook, By Application (2022-2030) ($MN)
  • Table 26 Global Automation in Biopharma Market Outlook, By Research & Development (2022-2030) ($MN)
  • Table 27 Global Automation in Biopharma Market Outlook, By Drug Discovery (2022-2030) ($MN)
  • Table 28 Global Automation in Biopharma Market Outlook, By Genomics and Proteomics (2022-2030) ($MN)
  • Table 29 Global Automation in Biopharma Market Outlook, By Biomanufacturing (2022-2030) ($MN)
  • Table 30 Global Automation in Biopharma Market Outlook, By Upstream Processing (2022-2030) ($MN)
  • Table 31 Global Automation in Biopharma Market Outlook, By Downstream Processing (2022-2030) ($MN)
  • Table 32 Global Automation in Biopharma Market Outlook, By Clinical Trials (2022-2030) ($MN)
  • Table 33 Global Automation in Biopharma Market Outlook, By Quality Control & Assurance (2022-2030) ($MN)
  • Table 34 Global Automation in Biopharma Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 35 Global Automation in Biopharma Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 36 Global Automation in Biopharma Market Outlook, By End User (2022-2030) ($MN)
  • Table 37 Global Automation in Biopharma Market Outlook, By Pharmaceutical Companies (2022-2030) ($MN)
  • Table 38 Global Automation in Biopharma Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 39 Global Automation in Biopharma Market Outlook, By Contract Research Organizations (CROs) (2022-2030) ($MN)
  • Table 40 Global Automation in Biopharma Market Outlook, By Academic and Research Institutions (2022-2030) ($MN)
  • Table 41 Global Automation in Biopharma Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 42 Global Automation in Biopharma Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.